by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract INTRODUCTION The availability of amyloid beta (Aβ) targeting therapies for Alzheimer’s disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation. METHODS We evaluated fully-automated Lumipulse...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) co-pathology with Lewy bodies (LB) is frequent and influences clinical manifestations and outcomes. Its significance in primary age-related tauopathy (PART) is unknown. We investigated the influence of LB on...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract INTRODUCTION The effects of sex and apolipoprotein E (APOE)—Alzheimer’s disease (AD) risk factors—on white matter microstructure are not well characterized. METHODS Diffusion magnetic resonance imaging data from nine well-established longitudinal...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in...
by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion Working Group (DE&I WG) was established to work with the ADNI3 Diversity Task Force to provide an industry perspective...
by Clinical Neuropsychologist | Friday, December 20, 2024 | Dementia
Abstract INTRODUCTION This study investigated the associations of brain age gap (BAG)—a biological marker of brain resilience—with life exposures, neuroimaging measures, biological processes, and cognitive function. METHODS We derived BAG by subtracting predicted...
